Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
02
2022
revised:
13
06
2022
accepted:
16
06
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
11
10
2022
Statut:
epublish
Résumé
Women with locally advanced/high-risk triple-negative breast cancer treated with the current standard chemotherapy continue to have a poor prognosis. High-dose chemotherapy with autologous stem cell transplant as treatment for locally advanced/high-risk breast cancer remains controversial due to a lack of survival benefit seen in previous phase III trials. However, these trials evaluated a heterogeneous group of patients with different receptor subtypes. A marginal benefit was observed in certain subgroups. We report long-term outcomes of women with stage IIB or III triple-negative breast cancer treated with high-dose chemotherapy followed by autologous stem cell transplant at our institution between 1995 and 2001. This is a retrospective analysis of stage IIB or stage III triple-negative breast cancer treated with high-dose chemotherapy followed by autologous stem cell transplant. We excluded women with hormone-positive, HER2/neu-positive/unknown, and/or metastatic disease prior to transplant as per updated AJCC 7 Twenty-nine women (2 stage IIB and 27 stage III) were evaluated. The median age at diagnosis was 43 years (IQR: 40, 51). Eleven patients had 4-9 regional lymph nodes (LN) involved and 16 had 10+ involved LNs. Four patients had T4 or inflammatory breast cancer and two had ipsilateral supraclavicular LNs involved. The median follow-up time is 16 years (95% CI: 12, 19, range <1-19 y) posttransplant. The median overall survival was 15 years (95% CI: 3, 19); the median DFS was 14 years (95% CI: 1, 19). This study of locally advanced/high-risk triple-negative breast cancer treated with adjuvant high-dose chemotherapy and autologous stem cell transplant reveals high overall survival rate. With the current improvement in treatment-related mortality, re-evaluating this approach in this subset of high-risk breast cancer in prospective randomized studies may be worthwhile.
Identifiants
pubmed: 36213836
doi: 10.1155/2022/3472324
pmc: PMC9546640
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3472324Informations de copyright
Copyright © 2022 Bayan Al-Share et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
J Clin Oncol. 1993 Jun;11(6):1132-43
pubmed: 8501500
Clin Breast Cancer. 2007 Feb;7(6):471-9
pubmed: 17386124
Breast Cancer Res Treat. 2008 May;109(1):123-39
pubmed: 17578664
J Clin Oncol. 2009 Mar 10;27(8):1168-76
pubmed: 19204205
Clin Cancer Res. 2011 Mar 1;17(5):1082-9
pubmed: 21233401
Cancer Biol Med. 2015 Jun;12(2):106-16
pubmed: 26175926
Lancet. 2005 Dec 3;366(9501):1935-44
pubmed: 16325695
J Clin Oncol. 2017 Aug 10;35(23):2647-2655
pubmed: 28398846
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
N Engl J Med. 2000 Apr 13;342(15):1069-76
pubmed: 10760307
Biol Blood Marrow Transplant. 2000;6(2A):198-203
pubmed: 10816028
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Breast Cancer Res Treat. 2010 Aug;123(1):149-57
pubmed: 20037779
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Biol Blood Marrow Transplant. 2014 Apr;20(4):501-6
pubmed: 24374214
Curr Stem Cell Res Ther. 2007 Jan;2(1):65-82
pubmed: 18220892
J Clin Oncol. 2011 Aug 20;29(24):3214-23
pubmed: 21768471
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
J Clin Oncol. 1988 Sep;6(9):1368-76
pubmed: 3047332
Cancer Treat Rev. 2007 Jun;33(4):325-37
pubmed: 17382477
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
JAMA Oncol. 2020 Apr 1;6(4):528-534
pubmed: 31999296
Biol Blood Marrow Transplant. 2016 Mar;22(3):475-81
pubmed: 26723932
J Clin Oncol. 2021 Aug 10;39(23):2539-2551
pubmed: 34092112
N Engl J Med. 2007 Oct 11;357(15):1496-506
pubmed: 17928597
J Clin Oncol. 1986 May;4(5):646-54
pubmed: 3517240
Health Aff (Millwood). 2001 Sep-Oct;20(5):101-17
pubmed: 11558695
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
JAMA. 2006 Jun 7;295(21):2492-502
pubmed: 16757721
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
J Clin Oncol. 1992 Jan;10(1):102-10
pubmed: 1727912
Breast J. 2009 Nov-Dec;15(6):593-602
pubmed: 19764994